CWM
THRX

Castle Wealth Management’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Castle Wealth Management’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50
Closed – – 688
2022
Q3 		$0 Hold
50
– – ﹤0.01% 756
2022
Q2 		$0 Buy
+50
New +$413 ﹤0.01% 717

Other funds holding THRX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Castle Wealth Management's THRX Position: Q4 2022 in Review

Castle Wealth Management sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q4 2022, closing a stake of 50 shares.

Castle Wealth Management first reported a position in THRX in Q2 2022 and held it in 2 quarters. The position peaked at $0 in Q3 2022. 47 funds tracked by Wall St. Rank hold THRX as of Q4 2022.

  • Castle Wealth Management reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Castle Wealth Management sold 50 Theseus Pharmaceuticals, Inc. Common Stock shares in Q4 2022.
  • Castle Wealth Management first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Castle Wealth Management's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $0 in Q3 2022.
  • 47 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Castle Wealth Management's 13F filing for Q4 2022, filed 9 Feb 2023.